An AOP analysis of selective serotonin reuptake inhibitors (SSRIs) for fish

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms. Using an Adverse Outcome Pathway (AOP) framework, this review examines the similarities and differences between the mammalian and teleost fish SSRI target, the serotonin transporter (SERT; SLC6A4), and the downstream impacts of elevated extracellular serotonin (5-HT; 5-hydroxytryptamine), the consequence of SERT inhibition, on organ systems and physiological processes within teleost fish. This review also intends to reveal potentially understudied endpoints for SSRI toxicity based on what is known to be controlled by 5-HT in fish.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalComparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology
Volume197
DOIs
StatePublished - Jul 1 2017

Fingerprint

Serotonin Uptake Inhibitors
Fishes
Serotonin
Pharmaceutical Services
Mammals
Physiological Phenomena
Aquatic Organisms
Serotonin Plasma Membrane Transport Proteins
Antidepressive Agents
Vertebrates
Pharmacokinetics
Pharmaceutical Preparations

Keywords

  • 5-HT
  • Adverse Outcome Pathway
  • Antidepressant
  • Aquatic
  • Behavior
  • Fish
  • Fluoxetine
  • Physiology
  • Read-Across Hypothesis
  • SERT
  • Sertraline
  • Transport
  • Vertebrates

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{8db5f10427ca4acab3654b097d0eaa24,
title = "An AOP analysis of selective serotonin reuptake inhibitors (SSRIs) for fish",
abstract = "Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms. Using an Adverse Outcome Pathway (AOP) framework, this review examines the similarities and differences between the mammalian and teleost fish SSRI target, the serotonin transporter (SERT; SLC6A4), and the downstream impacts of elevated extracellular serotonin (5-HT; 5-hydroxytryptamine), the consequence of SERT inhibition, on organ systems and physiological processes within teleost fish. This review also intends to reveal potentially understudied endpoints for SSRI toxicity based on what is known to be controlled by 5-HT in fish.",
keywords = "5-HT, Adverse Outcome Pathway, Antidepressant, Aquatic, Behavior, Fish, Fluoxetine, Physiology, Read-Across Hypothesis, SERT, Sertraline, Transport, Vertebrates",
author = "Mcdonald, {Danielle M}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.cbpc.2017.03.007",
language = "English (US)",
volume = "197",
pages = "19--31",
journal = "Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology",
issn = "1532-0456",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - An AOP analysis of selective serotonin reuptake inhibitors (SSRIs) for fish

AU - Mcdonald, Danielle M

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms. Using an Adverse Outcome Pathway (AOP) framework, this review examines the similarities and differences between the mammalian and teleost fish SSRI target, the serotonin transporter (SERT; SLC6A4), and the downstream impacts of elevated extracellular serotonin (5-HT; 5-hydroxytryptamine), the consequence of SERT inhibition, on organ systems and physiological processes within teleost fish. This review also intends to reveal potentially understudied endpoints for SSRI toxicity based on what is known to be controlled by 5-HT in fish.

AB - Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms. Using an Adverse Outcome Pathway (AOP) framework, this review examines the similarities and differences between the mammalian and teleost fish SSRI target, the serotonin transporter (SERT; SLC6A4), and the downstream impacts of elevated extracellular serotonin (5-HT; 5-hydroxytryptamine), the consequence of SERT inhibition, on organ systems and physiological processes within teleost fish. This review also intends to reveal potentially understudied endpoints for SSRI toxicity based on what is known to be controlled by 5-HT in fish.

KW - 5-HT

KW - Adverse Outcome Pathway

KW - Antidepressant

KW - Aquatic

KW - Behavior

KW - Fish

KW - Fluoxetine

KW - Physiology

KW - Read-Across Hypothesis

KW - SERT

KW - Sertraline

KW - Transport

KW - Vertebrates

UR - http://www.scopus.com/inward/record.url?scp=85018653421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018653421&partnerID=8YFLogxK

U2 - 10.1016/j.cbpc.2017.03.007

DO - 10.1016/j.cbpc.2017.03.007

M3 - Review article

VL - 197

SP - 19

EP - 31

JO - Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology

JF - Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology

SN - 1532-0456

ER -